专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明专利

PE03372007A1 FORMULACIONES LIQUIDAS QUE COMPRENDEN UN MODULADOR O AGONISTA DEL RECEPTOR S1P 未知
公开(公告)号：PE03372007A1
公开(公告)日：2007-04-18
申请号：PE0009572006
申请日：2006-08-07
申请人： NOVARTIS AG
发明人： GEORGOUSIS VIVIAN , TONG WEI-QIN
IPC分类号： A61K9/08 , A61K31/00
CPC分类号： A61K47/10 , A61K9/0053 , A61K9/0095 , A61K31/00 , A61K31/137 , C07C215/28 , C07D205/04 , C07F9/141
摘要： REFERIDA A UN CONCENTRADO PARA DISOLUCION QUE COMPRENDE: A) UN MODULADOR O AGONISTA DEL RECEPTOR DE FOSFATO DE ESFINGOSINA-1 (S1P) DE FORMULA R3ZR2ZN-C(CH3)(Z)-CH2R1Z (FORMULA X), DONDE Z ES H, ALQUILO C1-C6, ALQUENILO C2-C6, FENILO, ENTRE OTROS; R1Z ES OH, ACILOXI, ENTRE OTROS; R2Z Y R3Z SON H, ALQUILO C1-C4 O ACILO Y B) GLICOL PROPILENICO. SON MODULADORES O AGONISTAS DEL RECEPTOR S1P PREFERIDOS: 2-AMINO-2-[2-(4-OCTILFENILETIL)]PROPANO-1,3-DIOL, 2-AMINO-2-[4-(BENCILOXIFENILTIO)-2-CLOROFENIL]ETIL-1,3-PROPANO-DIOL, ENTRE OTROS. DICHO CONCENTRADO TAMBIEN PUEDE CONTENER GLICERINA, SIENDO LA RELACION ENTRE GLICERINA Y GLICOL PROPILENICO DE 5:95 A 25:75; ASIMISMO, DICHO CONCENTRADO ES UTIL EN EL TRATAMIENTO DE RECHAZO DE TRASPLANTE DE ORGANOS, TRATAMIENTO DE ENFERMEDADES AUTOINMUNES TALES COMO ESCLEROSIS MULTIPLE, ARTRITIS REUMATOIDE, ENTRE OTRAS

42. 发明专利

AU2006297444A1 New formulation 未知
公开(公告)号：AU2006297444A1
公开(公告)日：2007-04-12
申请号：AU2006297444
申请日：2006-09-25
申请人： NOVARTIS AG
发明人： TONG WEI-QIN , JOSHI YATINDRA , VASANTHAVADA MADHAV , KOWALSKI JAMES , LAKSHMAN JAY PARTHIBAN , ROYCE ALAN EDWARD
IPC分类号： A61K9/20
摘要： This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.

43. 发明专利

CY1112305T1 ΣΚΕΥΑΣΜΑ ΠΟΥ ΠΕΡΙΕΧΕΙ ΜΕΤΦΟΡΜΙΝΗ ΚΑΙ ΒΙΛΔΑΓΛΙΠΤΙΝΗ 未知
公开(公告)号：CY1112305T1
公开(公告)日：2015-12-09
申请号：CY121100118
申请日：2012-02-02
申请人： NOVARTIS AG
发明人： JOSHI YATINDRA , KOWALSKI JAMES , LAKSHMAN JAY PARTHIBAN , ROYCE ALAN EDWARD , TONG WEI-QIN , VASANTHAVADA MADHAV
IPC分类号： A61K31/155 , A61K9/20 , A61K9/48 , A61K31/40 , A61K31/4439 , A61P3/10
摘要： Ηεφεύρεσηαναφέρεταισεένασκεύασμαπουπεριέχειέναναναστολέατηςδιπεπτιδυλπεπτιδάσης IV (DPP-IV) κατάπροτίμησητηβιλδαγλιπτίνηκαιμετφορμίνη, σεταμπλέτεςπουπεριέχουντέτοιεςσυνθέσειςκαιστιςδιαδικασίεςγιατηπαρασκευήτους.

44. 发明专利

BRPI0910545A2 processo contínuo para fazer composições farmacêuticas 未知
公开(公告)号：BRPI0910545A2
公开(公告)日：2015-09-29
申请号：BRPI0910545
申请日：2009-04-29
申请人： NOVARTIS AG
发明人： SERAJUDDIN ABUT T M , KOWALSKI JAMES , LAKSHMAN JAY PARTHIBAN , VASATHAVADA MADHAV , TONG WEI-QIN
IPC分类号： A61J3/02 , A61J3/10 , A61K9/20

45. 发明专利

MY148074A PHARMACEUTICAL COMPOSITIONS COMPRISING IMATINIB AND A RELEASE RETARDANT 未知
公开(公告)号：MY148074A
公开(公告)日：2013-02-28
申请号：MYPI20062055
申请日：2006-05-04
申请人： NOVARTIS AG
发明人： VASANTHAVADA MADHAV , LAKSHMAN JAY PARTHIBAN , TONG WEI-QIN , SERAJUDDIN ABU T M
IPC分类号： A61K9/20
摘要： SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF. THE PHARMACEUTICAL COMPOSITIONS FURTHER CONTAIN A RELEASE RETARDANT, FOR EXAMPLE A WATER SOLUBLE, A WATER SWELLABLE AND/OR A WATER INSOLUBLE POLYMER. THE PRESENT INVENTION ALSO FEATURES A PARTICULARLY USEFUL PROCESS OF MAKING SUCH SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS BY USING AN EXTRUDER.

46. 发明专利

AU2008309058B2 Galenical formulations of Aliskiren and Valsartan 未知
公开(公告)号：AU2008309058B2
公开(公告)日：2012-08-09
申请号：AU2008309058
申请日：2008-09-24
申请人： NOVARTIS AG
发明人： MATHARU AMOL SINGH , BOCK MICHAELA ANNA MARIA , WOLF MARIE-CHRISTINE , WEN HONG , LOGGIA NICOLETTA , BABIOLE SAUNIER MAGGY , BARGENDA NICOLE , HIRSCH STEFAN , VIPPAGUNTA SUDHA , BUSS BRUNO , KOWALSKI JAMES , TONG WEI-QIN , ADLER SABINE , ALTENBURGER RALF , KELLER PATRICE FRANCOIS , KOCHHAR CHARU , LAKSHMAN JAY PARTHIBAN , TAILLEMITE JULIEN , CURDY CATHERINE , LI SHOUFENG , GHOSH INDRAJIT
IPC分类号： A61K9/22 , A61K9/20 , A61K9/24 , A61K9/48 , A61K9/50 , A61K31/165 , A61K31/41 , A61K45/06
摘要： The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.

47. 发明专利

MY145111A LIQUID FORMULATIONS 未知
公开(公告)号：MY145111A
公开(公告)日：2011-12-30
申请号：MYPI20063826
申请日：2006-08-08
申请人： NOVARTIS AG
发明人： GEORGOUSIS VIVIAN CHRISTINE , TONG WEI-QIN
IPC分类号： A61K9/08
摘要： LIQUID FORMULATIONS DISCLOSED IS A CONCENTRATE FOR DILUTION COMPRISING A SLP RECEPTOR AGONIST OR A PHAN,NACEUTICALLY ACCEPTABLE SALT THEREOF, PROPYLENE GLYCOL AND OPTIONALLY GLYCERIN. THIS FORMULATION IS ADAPTED FOR PATIENTS IN A DIFFICULT CONDITION TO SWALLOW. C3 @ 2-'6 O6

48. 发明专利

NZ585116A Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride 未知
公开(公告)号：NZ585116A
公开(公告)日：2011-12-22
申请号：NZ58511606
申请日：2006-05-08
申请人： NOVARTIS AG
发明人： VASANTHAVADA MADHAV , LAKSHMAN JAY , TONG WEI-QIN , SERAJUDDIN ABU T M , JOSHI YATINDRA , KOWALSKI JAMES
IPC分类号： A61K31/155 , A61K9/16 , A61K9/20
摘要： A process for making an oral dosage form of a pharmaceutical composition comprising the steps of: (a) combining a therapeutic compound selected from the group consisting of metoclopramide and propantheline bromide; aluminum trisilicate, aluminium hydroxide, cimetidine, phenylbutazone, indomethacin, naproxen, ibuprofen, flurbiprofen, diclofenac, dexamethasone, prednisone, prednisolone, glyceryl trinitrate, isosorbide dinitrate, pentaerythritol tetranitrate , soloctiditum, vincamine, naftidrofuryl oxalate, co-dergocrine mesylate, cyclandelate, papaverine, nicotinic acid, erythromycin stearate, cephalexin, nalidixic acid, tetracycline hydrochloride, ampicillin, flucolaxacillin sodium, hexamine mandelate, hexamine hippurate, fluazepam, diazepam, temazepam, amitryptyline, doxepin, lithium carbonate, lithium sulfate, chlorpromazine, thioridazine, trifluperazine, fluphenazine, piperothiazine, haloperidol, maprotiline hydrochloride, imipramine, desmethylimipramine, methylphenidate, ephedrine, epinephrine, isoproterenol, amphetamine sulfate, amphetamine hydrochloride, diphenhydramine, diphenylpyraline, chlorpheniramine, brompheniramine, bisacodyl, magnesium hydroxide, dioctyl sodium sulfosuccinate, ascorbic acid, alpha tocopherol, thiamine, pyridoxine, dicyclomine, diphenoxylate, verapamil, nifedepine, diltiazem, procainamide, disopyramide, bretylium tosylate, quinidine sulfate, quinidine gluconate, propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril, hydralazine, ergotamine, epsilon aminocaproic acid, protamine sulfate, acetylsalicylic acid, acetaminophen, codeine phosphate, codeine sulfate, oxycodone, dihydrocodeine tartrate, oxycodeinone, morphine, heroin, nalbuphine, butorphanol tartrate, pentazocine hydrochloride, cyclazacine, pethidine, buprenorphine, scopolamine, mefenamic acid, phenytoin sodium, sodium valproate, dantrolene sodium, tolbutamide, diabenase glucagon, insulin, triiodothyronine, thyroxine, propylthiouracil, furosemide, chlorthalidone, hydrochlorthiazide, spironolactone, triampterene, ritodrine, fenfluramine hydrochloride, phentermine, diethylproprion hydrochloride, aminophylline, theophylline, salbutamol, orciprenaline sulphate, terbutaline sulphate, guaniphenesin, dextromethorphan, noscapine, carbocisteine, cetylpyridinium chloride, tyrothricin, chiorhexidine, phenylpropanolamine, pseudoephedrine, dichtoraiphenazone, nitrazepam, promethazine theoclate, ferrous sulphate, folic acid, calcium gluconate, sulphinpyrazone, allopurinol, and probenecid with at least one granulating component to form a mixture, wherein said granulating component is a polymer (which may be selected from the group consisting of water-soluble polymers, water-swellable polymers, and water-insoluble polymers) having a Tg less than the melting point of said therapeutic compound; (b) kneading said mixture in an extruder while heating said mixture to a heating temperature less than a melting point of said therapeutic compound and greater than or equal to the Tg of said polymer; (c) extruding said mixture to form granules; and, (d) compressing or molding said granules.

49. 发明专利

BRPI0806341A2 未知
公开(公告)号：BRPI0806341A2
公开(公告)日：2011-09-06
申请号：BRPI0806341
申请日：2008-01-08
申请人： NOVARTIS AG
发明人： BURANACHOKPAISAN THITIWAN , TONG WEI-QIN , JIANG WEN-LEI
IPC分类号： A61K47/10 , A61K31/4045 , A61K47/12 , A61K47/26 , A61P35/00
摘要： The present invention provides a stable parenteral formulation of histone deacetylase inhibitors.

50. 发明专利

NZ565696A Liquid formulations comprising an S1P receptor modulator or agonist and propylene glycol 未知
公开(公告)号：NZ565696A
公开(公告)日：2011-06-30
申请号：NZ56569606
申请日：2006-08-08
申请人： NOVARTIS AG
发明人： GEORGOUSIS VIVIAN , TONG WEI-QIN
IPC分类号： A61K9/08 , A61K31/00
摘要： Disclosed is a pharmaceutical concentrate for dilution comprising: about 5-20% by weight of a S1P receptor modulator or agonist selected from 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propane-diol, or a corresponding phosphate thereof, and 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}- azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof; and about 65-95% by weight of propylene glycol. The composition may also include preservatives and flavours. Also disclosed is the use of the concentrate for immunosuppression, and for treating or preventing organ or tissue transplant rejection, autoimmune disease, inflammatory conditions, multiple sclerosis, arthritis, inflammatory bowel disease, hepatitis, viral myocarditis, or viral diseases caused by viral myocarditis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式